GMS | Deutscher Rheumatologiekongress 2024 | Baseline characteristics, disease activity, patient-reported outcomes (PROs) and safety in 465 patients with rheumatoid arthritis (RA) treated with filgotinib in Germany: Up to 18-month interim results from FILOSOPHY

Table 1: Baseline characteristics, cardiovascular risk factors/comorbidities and study treatment

gms | German Medical Science